CN101657199A - 帮助治疗化学疗法诱导的神经病的方法和药物制剂 - Google Patents

帮助治疗化学疗法诱导的神经病的方法和药物制剂 Download PDF

Info

Publication number
CN101657199A
CN101657199A CN200780028717A CN200780028717A CN101657199A CN 101657199 A CN101657199 A CN 101657199A CN 200780028717 A CN200780028717 A CN 200780028717A CN 200780028717 A CN200780028717 A CN 200780028717A CN 101657199 A CN101657199 A CN 101657199A
Authority
CN
China
Prior art keywords
cisplatin
pharmaceutical formulation
leteprinin
treatment
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780028717A
Other languages
English (en)
Chinese (zh)
Inventor
古鲁·雷迪
多瑞亚·米若卓斯基
路吉·莱纳兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spectrum Pharmaceuticals Inc
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of CN101657199A publication Critical patent/CN101657199A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200780028717A 2006-08-01 2007-08-01 帮助治疗化学疗法诱导的神经病的方法和药物制剂 Pending CN101657199A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82108206P 2006-08-01 2006-08-01
US60/821,082 2006-08-01

Publications (1)

Publication Number Publication Date
CN101657199A true CN101657199A (zh) 2010-02-24

Family

ID=38744846

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780028717A Pending CN101657199A (zh) 2006-08-01 2007-08-01 帮助治疗化学疗法诱导的神经病的方法和药物制剂

Country Status (12)

Country Link
EP (1) EP2046335A2 (enExample)
JP (1) JP2009545619A (enExample)
KR (1) KR20090047501A (enExample)
CN (1) CN101657199A (enExample)
BR (1) BRPI0715504A2 (enExample)
CA (1) CA2659477A1 (enExample)
IL (1) IL196824A0 (enExample)
MX (1) MX2009001116A (enExample)
NO (1) NO20090279L (enExample)
RU (1) RU2009107123A (enExample)
WO (1) WO2008017000A2 (enExample)
ZA (1) ZA200900728B (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004448A2 (en) * 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions

Also Published As

Publication number Publication date
BRPI0715504A2 (pt) 2014-05-06
EP2046335A2 (en) 2009-04-15
IL196824A0 (en) 2009-11-18
RU2009107123A (ru) 2010-09-10
MX2009001116A (es) 2009-02-10
CA2659477A1 (en) 2008-02-07
KR20090047501A (ko) 2009-05-12
WO2008017000A3 (en) 2008-03-20
WO2008017000A8 (en) 2009-04-30
ZA200900728B (en) 2010-03-31
NO20090279L (no) 2009-02-26
JP2009545619A (ja) 2009-12-24
WO2008017000A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
Feldman et al. Effect of magnesium given 1 hour after head trauma on brain edema and neurological outcome
DE69434121T2 (de) Pharmazeutische zusammensetzung zur immunverstärkenden therapie
EP2227234B1 (en) Method for inducing hepatocyte proliferation and uses thereof
US20080214569A1 (en) Use of phosphatases to treat tumors overexpressing N-CoR
WO2007092414A2 (en) Use of phosphatases to treat tumors overexpressing n-cor
Somberg et al. Localization of the neurally mediated arrhythmogenic properties of digitalis
US12357665B2 (en) Pharmaceutical compositions and uses thereof in treating muscle atrophy
AU673175B2 (en) Glutathione as chemoprotective agent
DK3099307T3 (en) Use of cladribine for the treatment of neuromyelitis optica
US20250082688A1 (en) Compositions and methods for williams syndrome (ws) therapy
Xing et al. Role of cerebrospinal fluid-contacting nucleus in sodium sensing and sodium appetite
Kitamura et al. Gabapentin inhibits bortezomib-induced mechanical allodynia through supraspinal action in mice
US9328060B2 (en) J-series prostaglandin-ethanolamides as novel therapeutics
EP2289520A1 (de) Verwendung von Acetylsalicylsäure zur Prophylaxe und/oder Therapie von Influenzavirus Infekten.
Bridgman et al. Post-marketing surveillance of the Transiderm-Nitro patch in general practice
Wu et al. Enhancing KCNQ channel activity improves neurobehavioral recovery after spinal cord injury
Heit et al. Interference with glutamate antiporter system xc− enables post‐hypoxic long‐term potentiation in hippocampus
US8633165B2 (en) Neuroprotective effects of 2DG in traumatic brain injury
Kobayashi et al. Direct evidence that pancuronium and gallamine enhance the release of norepinephrine from the atrial sympathetic nerve by inhibiting prejunctional muscarinic receptors
KR20090047501A (ko) 화학요법에 의해 유발된 신경병증의 치료에 기여하는 방법 및 약학 제제
RU2516027C2 (ru) Комбинация противораковых агентов
EP2568807B1 (en) Phenoxyalkyl pyridinium oxime therapeutics for treatment of organophosphate poisoning
US20250049811A1 (en) Methods of treating pancreatic cancer by using bet inhibitor and parp inhibitor
Popović et al. Effects of metformin and its combinations with other repurposed drugs on fibrosarcoma in hamsters
Vasin et al. Radioprotective Properties of Indralin and Essentiale N for Separate and Combined Application under Fractionated γ-Irradiation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100224